Ebos Group Ltd
EBO: XNZE (NZL)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|.p | LOCK|?v?jB | LOCK|>^ksYbW! |
Ebos Group Earnings: Shares Undervalued, With Margins Poised to Expand Near-Term
Ebos' interim 2026 underlying EBITDA grew 3% to AUD 300 million. Sales rose 13%, but profitability fell on lower-margin weight-loss drugs and a margin-dilutive New Zealand acquisition. Full-year guidance was reaffirmed, implying second-half underlying EBITDA lifting to roughly AUD 325 million.
